Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Bausch + Lomb Corporation ( (BLCO) ) has shared an announcement.
Bausch + Lomb reported strong financial results for the fourth quarter and full year of 2024, with revenue growth across all segments and geographies. The company achieved a 9% increase in fourth-quarter revenue and a 16% rise over the entire year compared to 2023. The results reflect successful execution in key areas such as the dry eye portfolio, contact lenses, and surgical products, with notable achievements including significant growth in consumer franchises like LUMIFY® and eye vitamins. The company also expanded its R&D efforts, highlighted by the acquisition of Elios Vision, positioning itself for continued innovation and market leadership.
More about Bausch + Lomb Corporation
Bausch + Lomb Corporation is a leading global eye health company that focuses on providing products and services that help people improve their vision and overall eye health. The company operates across various segments, including contact lenses, dry eye solutions, and surgical products, and is committed to long-term, profitable growth through strategic investments and a robust R&D pipeline.
YTD Price Performance: -8.83%
Average Trading Volume: 549,938
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $5.78B
For an in-depth examination of BLCO stock, go to TipRanks’ Stock Analysis page.
